$NVAX
NOVAVAX INC

2019 Q2 Form 10-Q Financial Statement

#000114420419023302 Filed on May 02, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2019 Q1 2018 Q4
Revenue $3.357M $3.982M $6.127M
YoY Change -68.84% -58.75% -41.15%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.600M $8.700M $9.200M
YoY Change 17.07% 0.0% 8.24%
% of Gross Profit
Research & Development $30.42M $35.47M $43.40M
YoY Change -31.71% -20.31% -12.68%
% of Gross Profit
Depreciation & Amortization $2.000M $1.900M $2.000M
YoY Change 0.0% -9.52% -4.76%
% of Gross Profit
Operating Expenses $30.42M $35.47M $52.60M
YoY Change -31.71% -20.31% -9.62%
Operating Profit -$36.67M -$40.22M
YoY Change -12.69% -7.56%
Interest Expense $3.403M $3.403M -$2.800M
YoY Change 0.0% 0.0% -9.68%
% of Operating Profit
Other Income/Expense, Net -$8.000K -$12.00K $0.00
YoY Change -108.25% -136.36%
Pretax Income -$39.60M -$43.20M -$49.30M
YoY Change -11.01% -6.9% -2.95%
Income Tax
% Of Pretax Income
Net Earnings -$39.60M -$43.22M -$49.33M
YoY Change -10.99% -6.76% -2.97%
Net Earnings / Revenue -1179.71% -1085.33% -805.19%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.685M -$2.118M -$2.568M
COMMON SHARES
Basic Shares Outstanding 469.5M 441.3M 382.9M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2019 Q1 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $72.00M $100.2M $92.10M
YoY Change -56.91% -30.32% -41.45%
Cash & Equivalents $78.24M $97.71M $70.15M
Short-Term Investments $0.00 $2.500M $22.00M
Other Short-Term Assets $38.20M $23.20M $4.321M
YoY Change 40.44% -37.63% -7.85%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $110.2M $123.4M $119.3M
YoY Change -43.29% -31.83% -41.33%
LONG-TERM ASSETS
Property, Plant & Equipment $19.90M $26.97M $28.43M
YoY Change -35.45% -16.75% -21.01%
Goodwill $51.25M $51.97M
YoY Change -2.98%
Intangibles $6.114M $6.541M
YoY Change -16.92%
Long-Term Investments
YoY Change
Other Assets $2.000M $11.73M $810.0K
YoY Change 146.61% 551.89% -6.79%
Total Long-Term Assets $79.20M $97.93M $88.70M
YoY Change -13.42% 2.97% -10.57%
TOTAL ASSETS
Total Short-Term Assets $110.2M $123.4M $119.3M
Total Long-Term Assets $79.20M $97.93M $88.70M
Total Assets $189.4M $221.3M $208.0M
YoY Change -33.73% -19.84% -31.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.300M $6.150M $9.301M
YoY Change -35.69% 6.03% 65.7%
Accrued Expenses $20.10M $13.88M $19.55M
YoY Change -8.81% -34.83% -33.98%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $41.50M $31.50M $45.54M
YoY Change -3.53% -29.85% -38.19%
LONG-TERM LIABILITIES
Long-Term Debt $319.9M $319.5M $319.2M
YoY Change 0.44% 0.44% 0.44%
Other Long-Term Liabilities $13.50M $17.46M $8.687M
YoY Change 41.81% 40.84% -15.55%
Total Long-Term Liabilities $333.4M $17.46M $8.687M
YoY Change 3402.1% -94.72% -15.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $41.50M $31.50M $45.54M
Total Long-Term Liabilities $333.4M $17.46M $8.687M
Total Liabilities $374.9M $371.9M $375.9M
YoY Change 0.37% -0.93% -7.0%
SHAREHOLDERS EQUITY
Retained Earnings -$1.342B -$1.299B
YoY Change 16.58%
Common Stock $4.699M $3.849M
YoY Change 18.91%
Preferred Stock
YoY Change
Treasury Stock (at cost) $2.450M $2.450M
YoY Change 0.0%
Treasury Stock Shares $455.4K $455.4K
Shareholders Equity -$185.5M -$150.6M -$167.9M
YoY Change
Total Liabilities & Shareholders Equity $189.4M $221.3M $208.0M
YoY Change -33.73% -19.84% -31.25%

Cashflow Statement

Concept 2019 Q2 2019 Q1 2018 Q4
OPERATING ACTIVITIES
Net Income -$39.60M -$43.22M -$49.33M
YoY Change -10.99% -6.76% -2.97%
Depreciation, Depletion And Amortization $2.000M $1.900M $2.000M
YoY Change 0.0% -9.52% -4.76%
Cash From Operating Activities -$30.00M -$50.61M -$45.20M
YoY Change -24.81% -23.41% 4.15%
INVESTING ACTIVITIES
Capital Expenditures -$500.0K -$800.0K -$500.0K
YoY Change 66.67% 300.0% -28.57%
Acquisitions
YoY Change
Other Investing Activities $2.500M $19.50M $48.90M
YoY Change -105.21% -5.8% 179.43%
Cash From Investing Activities $2.000M $18.71M $48.30M
YoY Change -104.14% -9.11% 187.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $55.24M
YoY Change 29.67%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 56.18M 3.900M
YoY Change -100.0% 27.91% -77.59%
NET CHANGE
Cash From Operating Activities -30.00M -50.61M -45.20M
Cash From Investing Activities 2.000M 18.71M 48.30M
Cash From Financing Activities 0.000 56.18M 3.900M
Net Change In Cash -28.00M 24.24M 7.000M
YoY Change -18.13% -1624.53% -176.09%
FREE CASH FLOW
Cash From Operating Activities -$30.00M -$50.61M -$45.20M
Capital Expenditures -$500.0K -$800.0K -$500.0K
Free Cash Flow -$29.50M -$49.81M -$44.70M
YoY Change -25.51% -24.39% 4.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28426000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
97711000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70154000
CY2019Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
2484000
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
21980000
CY2019Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
6628000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
10847000
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
16571000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
16295000
CY2019Q1 us-gaap Assets Current
AssetsCurrent
123394000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
119276000
CY2019Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1860000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
958000
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
26972000
CY2019Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6114000
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6541000
CY2019Q1 us-gaap Goodwill
Goodwill
51245000
CY2018Q4 us-gaap Goodwill
Goodwill
51967000
CY2019Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11734000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
810000
CY2019Q1 us-gaap Assets
Assets
221319000
CY2018Q4 us-gaap Assets
Assets
207978000
CY2019Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
6150000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9301000
CY2019Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13881000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19550000
CY2019Q1 us-gaap Interest Payable Current
InterestPayableCurrent
2031000
CY2018Q4 us-gaap Interest Payable Current
InterestPayableCurrent
5078000
CY2019Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
5943000
CY2018Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
10010000
CY2019Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3491000
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1600000
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
31496000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
45539000
CY2019Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3399000
CY2018Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2500000
CY2018Q4 us-gaap Liabilities
Liabilities
375913000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
3849000
CY2019Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
319543000
CY2018Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
319187000
CY2019Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
17464000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
8687000
CY2019Q1 us-gaap Liabilities
Liabilities
371902000
CY2019Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
4699000
CY2019Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1201853000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1140964000
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1342325000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1299107000
CY2019Q1 us-gaap Treasury Stock Value
TreasuryStockValue
2450000
CY2018Q4 us-gaap Treasury Stock Value
TreasuryStockValue
2450000
CY2019Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-12360000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-11191000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-150583000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-167935000
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
221319000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
207978000
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
61260970
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
45126499
CY2019Q1 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
12400000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
11200000
CY2019Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
2484000
CY2019Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2019Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2018Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
21985000
CY2018Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2018Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5000
CY2019Q1 us-gaap Revenues
Revenues
3982000
CY2018Q1 us-gaap Revenues
Revenues
9653000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35473000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44514000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8732000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8652000
CY2019Q1 us-gaap Costs And Expenses
CostsAndExpenses
44205000
CY2018Q1 us-gaap Costs And Expenses
CostsAndExpenses
53166000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-40223000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-43513000
CY2019Q1 us-gaap Investment Income Net
InvestmentIncomeNet
420000
CY2018Q1 us-gaap Investment Income Net
InvestmentIncomeNet
531000
CY2019Q1 us-gaap Interest Expense
InterestExpense
3403000
CY2018Q1 us-gaap Interest Expense
InterestExpense
3403000
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12000
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
33000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-43218000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-46352000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
408843000
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
336972000
CY2019Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
2484000
CY2018Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
21980000
CY2018Q4 us-gaap Goodwill
Goodwill
51967000
CY2019Q1 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-722000
CY2019Q1 us-gaap Goodwill
Goodwill
51245000
CY2019Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
11650000
CY2019Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5536000
CY2019Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
6114000
CY2018Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
12130000
CY2018Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5589000
CY2018Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
6541000
CY2019Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000
CY2016Q1 us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
10000000
CY2019Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
325000000
CY2016Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
325000000
CY2018Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
325000000
CY2019Q1 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
5457000
CY2018Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
5813000
CY2019Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
3047000
CY2018Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
3047000
CY2019Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
356000
CY2018Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
356000
CY2019Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
3403000
CY2018Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
3403000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.38
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.50
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
300000
CY2019Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
41000000
CY2019Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y6M
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
5000
CY2018Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8000
CY2019Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1174000
CY2018Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-462000
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1169000
CY2018Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-454000
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44387000
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46806000
CY2019Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1939000
CY2018Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2079000
CY2019Q1 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2018Q1 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
-4381000
CY2019Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
356000
CY2018Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
356000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5558000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5245000
CY2019Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
14000
CY2018Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
435000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
296000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
0
CY2019Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-11853000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-13293000
CY2019Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3167000
CY2018Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-9247000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50607000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-66075000
CY2019Q1 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
805000
CY2018Q1 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
150000
CY2019Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
22000000
CY2018Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
22721000
CY2019Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
2484000
CY2018Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1984000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
18711000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
20587000
CY2019Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
55239000
CY2018Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
42599000
CY2019Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
942000
CY2018Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1325000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
56181000
CY2019Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-88000
CY2018Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
47000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
24240000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1590000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
43924000
CY2019Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-45000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
384450607
CY2019Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
455430
CY2018Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
455430
CY2018Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-26000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
81959000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
135431000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
106199000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
133841000
CY2019Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
194000
CY2018Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
62000
CY2019Q1 us-gaap Interest Paid Net
InterestPaidNet
6094000
CY2018Q1 us-gaap Interest Paid Net
InterestPaidNet
6094000
CY2019Q1 nvax Cash Cash Equivalents Marketable Securities Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsMarketableSecuritiesRestrictedCashAndRestrictedCashEquivalents
108700000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0
CY2019Q1 nvax Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Forfeiture Rate
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
0.0
CY2018Q1 nvax Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Forfeiture Rate
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
0.0
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5558000
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5245000
CY2019Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
469909313
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
469453883
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
384906037
CY2019Q1 us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note 1 &#8211; Organization</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Novavax, Inc. (&#8220;Novavax,&#8221; and together with its wholly owned subsidiary, Novavax AB, the &#8220;Company&#8221;) is a late-stage biotechnology company focused on the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The Company&#8217;s vaccine candidates, including ResVax<div style="vertical-align: super;font-size: smaller;display:inline;">TM</div> and NanoFlu<div style="vertical-align: super;font-size: smaller;display:inline;">TM</div>, are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis and may elicit differentiated immune responses, which may be more efficacious than naturally occurring immunity or traditional vaccines. The Company&#8217;s technology targets a variety of infectious diseases.</div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.25in; margin-top: 0px; text-align: justify; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates</div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
6628000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
10847000
CY2019Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1860000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
958000
CY2019Q1 us-gaap Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
P12M
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
3000000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-167935000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5558000
CY2019Q1 nvax Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
942000
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
55239000
CY2019Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
5000
CY2019Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1174000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-150583000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-101732000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5245000
CY2018Q1 nvax Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
1325000
CY2018Q1 nvax Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodValue
0
CY2018Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
42599000
CY2018Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
8000
CY2018Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-462000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
-99369000
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
20887000
CY2019Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1525
CY2019Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y6M29D
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
5008000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5311000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5292000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5409000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
4919000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
5754000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
31693000
CY2019Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
10806000
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
20887000
CY2019Q1 us-gaap Revenue Recognition Revenue Reductions
RevenueRecognitionRevenueReductions
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.25in; margin-top: 0px; text-align: justify; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Revenue Recognition</div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.25in; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company performs research and development under grant, license and clinical development agreements. Payments received in advance of work performed are recorded as deferred revenue.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px; text-align: justify; text-indent: 0.5in; background: none;">The Company&#8217;s current revenue primarily consists of revenue under its Grant Agreement with BMGF (see Note 11). The Company is reimbursed for certain costs that support development activities, including the Company&#8217;s global Phase 3 clinical trial in pregnant women in their third trimester, product licensing efforts and efforts to obtain World Health Organization (&#8220;WHO&#8221;) prequalification of its RSV F Vaccine for infants via maternal immunization (&#8220;ResVax&#8221;). The Company&#8217;s Grant Agreement does not provide a direct economic benefit to BMGF. Rather, the Company entered into an agreement with BMGF to make a certain amount of ResVax available and accessible at affordable pricing to people in certain low and middle income countries. Based on these circumstances, the Company does not consider BMGF to be a customer and concluded the Grant Agreement is outside the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09,&#160;<div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Revenue from Contracts with Customers (Topic 606)</div>. Payments received under the Grant Agreement are considered conditional contributions under the scope of ASC 958-605,&#160;<div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Not-for-Profit Entities &#8211; Revenue Recognition</div>, and are recorded as deferred revenue until the period in which such research and development activities are performed and revenue can be recognized.</div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company analyzed the Grant Agreement with BMGF to determine whether the payments received should be recorded as revenue or as a reduction to research and development expenses. In reaching the determination that such payments should be recorded as revenue, management considered a number of factors, including whether the Company is principal under the arrangement, and whether the arrangement is significant to, and part of, the Company&#8217;s core operations. Further, management has consistently applied its policy of presenting such amounts as revenue.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1115000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
607000
CY2019Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
505000
CY2019Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
560000
CY2019Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
401000
CY2019Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
401000
CY2019Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
401000
CY2019Q1 nvax Finite Lived Intangible Assets Amortization Expense Year Six
FiniteLivedIntangibleAssetsAmortizationExpenseYearSix
401000
CY2019Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1265000
CY2019Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
170000
CY2019Q1 us-gaap Lease Cost
LeaseCost
1435000
CY2019Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1646000
CY2019Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
11893000
CY2019Q1 nvax Base Rent
BaseRent
1700000
CY2019Q1 dei Document Type
DocumentType
10-Q
CY2019Q1 dei Amendment Flag
AmendmentFlag
false
CY2019Q1 dei Document Period End Date
DocumentPeriodEndDate
2019-03-31
CY2019Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2019Q1 dei Entity Registrant Name
EntityRegistrantName
NOVAVAX INC
CY2019Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001000694
CY2019Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2019Q1 dei Trading Symbol
TradingSymbol
NVAX
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
469453883
CY2019Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019Q1 dei Entity Small Business
EntitySmallBusiness
true

Files In Submission

Name View Source Status
0001144204-19-023302-index-headers.html Edgar Link pending
0001144204-19-023302-index.html Edgar Link pending
0001144204-19-023302.txt Edgar Link pending
0001144204-19-023302-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
nvax-20190331.xml Edgar Link completed
nvax-20190331.xsd Edgar Link pending
nvax-20190331_cal.xml Edgar Link unprocessable
nvax-20190331_def.xml Edgar Link unprocessable
nvax-20190331_lab.xml Edgar Link unprocessable
nvax-20190331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv519341_10q.htm Edgar Link pending
tv519341_ex31-1.htm Edgar Link pending
tv519341_ex31-2.htm Edgar Link pending
tv519341_ex32-1.htm Edgar Link pending
tv519341_ex32-2.htm Edgar Link pending